30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study
about
Progress in adjuvant chemotherapy for breast cancer: an overviewCurrent treatment of early breast cancer: adjuvant and neoadjuvant therapySeeding of epithelial cells into circulation during surgery for breast cancer: the fate of malignant and benign mobilized cellsConcurrent radiotherapy does not affect adjuvant CMF delivery but is associated with increased toxicity in women with early breast cancer.Sunitinib for Asian patients with advanced renal cell carcinoma: a comparable efficacy with different toxicity profiles.Risk factors for chemotherapy-induced neutropenia occurrence in breast cancer patients: data from the INC-EU Prospective Observational European Neutropenia Study.Risk and consequences of chemotherapy-induced neutropenic complications in patients receiving daily filgrastim: the importance of duration of prophylaxis.Adjuvant radiotherapy and chemotherapy in breast cancer: 30 year follow-up of survival.Dose intensity in early-stage breast cancer: a community practice experienceGranulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysisSULT1A1 rs9282861 polymorphism-a potential modifier of efficacy of the systemic adjuvant therapy in breast cancer?Comparative benefit from small tumour size and adjuvant chemotherapy: clues for explaining breast cancer mortality decline.Economic costs of chemotherapy-induced febrile neutropenia among patients with non-Hodgkin's lymphoma in European and Australian clinical practiceManagement of breast cancer patients with chemotherapy-induced neutropenia or febrile neutropeniaTesting for HER2 in Breast Cancer: A Continuing Evolution.Neutrophil gelatinase-associated lipocalin (NGAL) predicts response to neoadjuvant chemotherapy and clinical outcome in primary human breast cancer.Technical evaluation of methods for identifying chemotherapy-induced febrile neutropenia in healthcare claims databases.Assessing the efficacy of targeted therapy using circulating epithelial tumor cells (CETC): the example of SERM therapy monitoring as a unique tool to individualize therapy.Comparison of CVF (Cyclophosphamide+Vinorelbine+5-Fluorouracil) and CMF (Cyclophosphamide+Methotrexate+5-Fluorouracil) Adjuvant Chemotherapy in Early Breast Cancer.Cytokeratin-19 mRNA-positive circulating tumor cells during follow-up of patients with operable breast cancer: prognostic relevance for late relapse.Effects of repeated administration of chemotherapeutic agents tamoxifen, methotrexate, and 5-fluorouracil on the acquisition and retention of a learned response in miceEpidemiology and characteristics of febrile neutropenia in oncology patients from Spanish tertiary care hospitals: PINNACLE study.In Vivo Long-Term Monitoring of Circulating Tumor Cells Fluctuation during Medical Interventions.Assessing the real-world cost-effectiveness of adjuvant trastuzumab in HER-2/neu positive breast cancerComparative clinical effectiveness of various 5-HT3 RA antiemetic regimens on chemotherapy-induced nausea and vomiting associated with hospital and emergency department visits in real world practice.The impact of chemotherapy dose intensity and supportive care on the risk of febrile neutropenia in patients with early stage breast cancer: a prospective cohort studyAdjuvant Metronomic CMF in a Contemporary Breast Cancer Cohort: What's Old Is New.Costs and outcomes associated with hospitalized cancer patients with neutropenic complications: A retrospective studyDistribution, clinicopathologic features and survival of breast cancer subtypes in Southern ChinaThe value of comparative effectiveness research: projected return on investment of the RxPONDER trial (SWOG S1007)Emerging drugs to replace current leaders in first-line therapy for breast cancer.Differential effect of adjuvant taxane-based and taxane-free chemotherapy regimens on the CK-19 mRNA-positive circulating tumour cells in patients with early breast cancerRisk of chemotherapy-induced febrile neutropenia in cancer patients receiving pegfilgrastim prophylaxis: does timing of administration matter?The prevention and management of distant metastases in women with breast cancer.Risk of chemotherapy-induced febrile neutropenia with early discontinuation of pegfilgrastim prophylaxis in US clinical practice.Dose dense cyclophosphamide, methotrexate, fluorouracil is feasible at 14-day intervals: a pilot study of every-14-day dosing as adjuvant therapy for breast cancer.Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V.Patterns and predictors of breast cancer chemotherapy use in Kaiser Permanente Northern California, 2004-2007.Patients' Perceptions of Physician-Patient Discussions and Adverse Events with Cancer Therapy.Significance of micrometastases: circulating tumor cells and disseminated tumor cells in early breast cancer.
P2860
Q26798078-7E6A8475-717A-45A2-861D-29EED84F46A1Q27011658-9350880F-5B54-439A-AAE3-71B63B1D1AE8Q27497448-B1355998-54F0-4C96-A7F0-B4F1D2C2E32BQ33370705-6FA80A0F-17B2-4878-85CD-6431DD0D543BQ33396613-0DCF7C9D-F652-40D3-AC35-39AA819B0E4EQ33543823-70E13A57-7FD8-4CE0-96BE-4ED315014607Q33602351-DF8FD108-A4FE-41A9-9A6A-8112C5B7BDBAQ33645931-23B51941-7EEA-45C3-BD0B-CD5690899A5FQ33847958-D9F9593F-9519-4928-A4C6-D48CC0961E69Q34029496-81C46D4A-4BD8-412D-9451-B1471DC0FBDCQ34307873-164027B9-C8DA-4492-BFFA-167110828D2FQ34325697-DBFAA0CA-AEF5-43FF-91A6-74C8B4DD37FDQ34390036-F5D57773-377D-40B7-B224-22C744E7BD36Q34403621-EDEFD74C-4218-42BF-93DB-2FEEB3C68A73Q34424285-ADA144B7-3308-4E27-9A07-961DBB2DD100Q34440998-38203D33-4D34-470E-B0E6-E692D2DF29EFQ34585066-BFDD8CF0-DA7A-4DA6-A2F2-EDCBB2B48478Q34779138-F242E6EE-5AA0-42C0-96EC-CC25A0DD4AF3Q35435580-EF6354F1-0EB0-4144-A91A-1B2473A7C298Q35558096-DB527BB7-8D1B-41ED-9B02-246F71F23E22Q35644334-DF7B53CC-851C-4E47-99CC-458D40AE6AF0Q35753638-1B434742-4005-468D-9ACA-C35AC7D4C162Q35772819-9F02D251-01A2-45EC-BF7E-A6E930BBEB9EQ35776211-0E334F41-E495-4B40-8E00-0A2B2099F768Q35854847-C5B09642-AD1E-4F0A-A08A-B4FBDEF58048Q35916166-F27D2018-65C7-41B1-AADE-51724900C7B0Q36055133-FD2FAF72-95B1-4F5A-BF22-EE07D237BE70Q36230869-502C8F53-5163-4051-AFBE-87AEA3E04E24Q36303808-EE95159A-B6A6-4AF4-8CB4-A530B8778228Q36364504-8EBCF163-5C9F-4ADA-9E31-DE21DAB3D987Q36580598-D40B2220-156A-4649-976B-4AE284A82C39Q36671882-2752581A-5CE9-4A83-A93C-5A6F302DFDBCQ36723903-353E8196-A372-47DD-9CA4-C5EA41C9E318Q36761407-41C63D29-5B65-4F5B-B0EB-F34A961814A8Q36840636-6C2035AA-A755-4057-90F3-3071A9DEF1B7Q36866229-21182349-E778-4630-A3A1-BD9F50709ADDQ37065597-8CA8C7D1-FA30-4E1C-971C-30483302708CQ37161492-A1879D76-E08F-42AF-B22F-8B99BD3EE4AEQ37262613-F975E206-75EC-4F88-A0AA-1F742D38CB14Q37328416-426B1A9F-0543-4E5A-8F07-5D1B3D52E10A
P2860
30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
30 years' follow up of randomi ...... le breast cancer: cohort study
@ast
30 years' follow up of randomi ...... le breast cancer: cohort study
@en
type
label
30 years' follow up of randomi ...... le breast cancer: cohort study
@ast
30 years' follow up of randomi ...... le breast cancer: cohort study
@en
prefLabel
30 years' follow up of randomi ...... le breast cancer: cohort study
@ast
30 years' follow up of randomi ...... le breast cancer: cohort study
@en
P2093
P2860
P50
P1433
P1476
30 years' follow up of randomi ...... le breast cancer: cohort study
@en
P2093
Gianni Bonadonna
Luca Gianni
Maria Grazia Daidone
Milvia Zambetti
Silvana Pilotti
P2860
P356
10.1136/BMJ.38314.622095.8F
P407
P577
2005-01-13T00:00:00Z